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STUDY HIGHLIGHTS 
What is current knowledge? 
• The gene variant PNPLA3 rs738409 is an established risk factor for the development of 
alcohol-related cirrhosis and for the subsequent development of hepatocellular 
carcinoma (HCC) within this population  
• Two other risk variants, TM6SF2 rs58542926 and MBOAT7 rs641738, are associated 
with the development of alcohol-related cirrhosis but their role in the subsequent 
development of HCC is unclear  
 
What is new here? 
• While PNPLA3 rs738409 is confirmed as a risk factor for HCC in alcoholic cirrhotics, the 
present study identifies TM6SF2 rs58542926 as an independent risk factor for the 
development of HCC in people with alcohol-related cirrhosis  
• The dual carriage of these risk variants in PNPLA3 and TM6SF2 accounts for almost 
50% of the attributable risk for the development of HCC in this population 
• In contrast to its role as a risk factor for alcoholic cirrhosis, MBOAT7 rs641738 does 
not seem to confer risk to HCC development in this risk group 
• Genotype-based risk stratification for patients with alcohol-related cirrhosis may guide 
the development of rational, cost-effective surveillance programmes to facilitate early 
HCC detection 
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ABSTRACT 
Objectives: Variants in patatin-like phospholipase domain-containing 3 (PNPLA3; rs738409), 
transmembrane 6 superfamily member 2 (TM6SF2; rs58542926) and membrane bound O-
acyltransferase domain containing 7 (MBOAT7; rs641738) are risk factors for the 
development of alcohol-related cirrhosis. Within this population, PNPLA3 rs738409 is also an 
established risk factor for the development of hepatocellular carcinoma (HCC). The aim of this 
study was to explore possible risk associations of TM6SF2 rs58542926 and MBOAT7 rs641738 
with HCC. 
Methods: Risk variants in PNPLA3, TM6SF2 and MBOAT7 were genotyped in 751 cases with 
alcohol-related cirrhosis and HCC and in 1165 controls with alcohol-related cirrhosis without 
HCC. Association with the risk of developing HCC was analyzed using multivariate logistic 
regression. 
Results: The development of HCC was independently associated with PNPLA3 rs738409 
(ORadjusted 1.84 [95% CI 1.55-2.18], p=1.85×10
-12
) and TM6SF2 rs58542926 (ORadjusted 1.66 
[1.30-2.13], p=5.13×10
-05
) using an additive model and after controlling for sex, age, body 
mass index and type 2 diabetes mellitus; the risk associated with carriage of MBOAT7 
rs641738 (ORadjusted 1.04 [0.88-1.24], p=0.61) was not significant. The population-attributable 
fractions were 43.5% for PNPLA3 rs738409, 11.5% for TM6SF2 rs58542926, and 49.9% for 
carriage of both variants combined. 
Conclusions: Carriage of TM6SF2 rs58542926 is an additional risk factor for the development 
of HCC in people with alcohol–related cirrhosis. Carriage of both PNPLA3 rs738409 and 
TM6SF2 rs58542926 accounts for half of the attributable risk for HCC in this population.  
Genotyping will allow for more precise HCC risk stratification of patients with alcohol-related 
cirrhosis, and genotype-guided screening algorithms would optimize patient care. 
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INTRODUCTION 
The incidence of hepatocellular carcinoma (HCC) is increasing and it is now the fifth most 
frequent cancer and third most frequent cause of cancer-related mortality world-wide [1-3]. 
In Western countries, the presence of cirrhosis is a major risk factor for the development of 
HCC which only rarely evolves in non-cirrhotic livers [1,4,5]. Persistent high alcohol 
consumption is the leading cause of cirrhosis in these areas. The prognosis of patients with 
HCC is grave as it is often detected only when it reaches an advanced stage.  
Between 5 to 15% of patients with alcohol-related cirrhosis are potentially at risk for 
developing HCC with a 5-year cumulative risk of around 8% [1]. Identifying disease-
modulating factors which render some individuals more susceptible to its development than 
others is clearly of major importance as it would allow more specific targeting of surveillance 
programmes. Older age, male sex, and more advanced liver disease at presentation, are 
known to be important predictors but do not account for more than a small proportion of the 
observed risk variance. Mounting evidence suggest that host genetic factors may significantly 
modify the risk for developing HCC. Thus, identifying these factors in patients with alcohol-
related cirrhosis is clearly of major importance. 
A single nucleotide polymorphism (SNP) rs738409 C>G in patatin-like phospholipase domain-
containing 3 (PNPLA3) is an established risk factor for the development of alcohol-related 
cirrhosis in Caucasian populations [6-9]. A recent meta-analysis of individual patient data from 
candidate gene studies has shown that the PNPLA3 rs738409 G allele is also an independent 
risk factor for the development of HCC in this patient population [10,11]. Recently, variants in 
two further genes viz. rs58542926 in transmembrane 6 superfamily member 2 (TM6SF2) and 
rs641738 in membrane bound O-acyltransferase domain containing 7 (MBOAT7) were 
identified as risk factors for the development of alcohol-related cirrhosis in a genome-wide 
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association study (GWAS) [12]. Although a proportion of the cases included in the GWAS had 
developed HCC, the numbers were too small to allow for a meaningful subset analysis. 
However, data from two candidate gene studies support a role for variants in or linked to 
TM6SF2 as potential risk factors for HCC development. Thus, Nischalke et al. found a 
significant association between rs2228603 in the gene coding for neurocan (NCAN) and the 
development of HCC in people with alcohol-related cirrhosis [13]; this variant is in close 
linkage disequilibrium with TM6SF2 rs58542926. Falleti et al. genotyped TM6SF2 rs58542926 
in 226 cases with alcohol-related cirrhosis of whom 75 (33%) had HCC [14]. The rs58542926 
T/*genotype was more frequent in those cases with HCC (adjusted odd ratio [OR] 2.57; 
p=0.035). They found no interaction between PNPLA3 rs738409 and TM6SF2 rs58542926 in 
relation to HCC risk. These preliminary findings need to be further explored. No studies have 
been undertaken, to date, to explore the possible risk association between MBOAT rs641738 
and the development of HCC in patients with alcohol-related cirrhosis. 
The aim of the present study was to determine whether variants in PNPLA3, TM6SF2 and 
MBOAT7 are risk factors for the development of HCC, alone or in synergy, in a large, well-
characterized population of people with alcohol-related cirrhosis.  
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METHODS 
Patient cohorts 
For purposes of this study cases were defined as people with alcohol-related cirrhosis and 
HCC and controls as people with alcohol-related cirrhosis but without evidence of HCC.  Cases 
and controls were recruited from Hepatology centres across Europe (Switzerland, Germany, 
United Kingdom) and were of self-reported Swiss German/German/British/Irish ancestry.   
The diagnosis of alcohol-related cirrhosis was established as described previously [12], and 
based on a history of prolonged, sustained alcohol intake of a minimum of 40g/day, if female, 
and 60g/day, if male, and histological examination of liver tissue; or compatible historical, 
clinical, laboratory, radiological and endoscopic features. Patients were excluded if they had 
any other potential cause of liver injury, although a proportion of the participants were 
overweight. The diagnosis of HCC was based on histological examination of tumour tissue or 
evidence on imaging, preferably using two modalities, of lesion that are hypervascular in the 
arterial phase with washout in the portal venous or delayed phases [15]. The severity of 
underlying alcohol-related liver injury was assessed using Pugh’s modification of the Child’s 
grading system [16].  
DNA preparation and genotyping 
DNA was prepared using the FlexiGene chemistry (Qiagen, Hilden, Germany). For preparation 
of genotyping, DNA samples were evaluated by gel electrophoresis and adjusted to 20-30 
ng/µl DNA content using the Picogreen fluorescent dye (Molecular Probes – Invitrogen, 
Carlsbad, Ca, USA) on a robotic platform using TECAN liquid handling equipment. One 
microliter of genomic DNA was amplified with the GenomiPhi (Amersham, Uppsala, Sweden) 
whole genome amplification kit and fragmented at 99°C for three minutes. Five ng of DNA 
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were dried overnight in TwinTec hardshell 384well plates (Eppendorf, Hamburg, Germany) at 
room temperature. Genotyping of PNPLA3 rs738409 (Assay ID HCV7241_10 ), TM6SF2 
rs58542926 (Assay ID HCV89463510_10), and MBOAT7 rs641738 (Assay ID HCV8716820_10) 
was performed using TaqMan® SNP Genotyping Assays and chemistries (Applied Biosystems, 
Foster City, CA, USA) on an automated platform with TECAN Freedom EVO and 384well TEMO 
liquid handling robots (TECAN, Männedorf, Switzerland) as described before.[12] 
All process data were logged and administered with a database-driven LIMS. Reactions were
 
completed and read in a 7900 HT TaqMan sequence detector system
 
(Applied Biosystems, 
Foster City, CA, USA). The amplification reaction was carried out with the TaqMan universal 
master mix. Thermal cycling conditions consisted of 1 cycle for 10 minutes
 
at 95°C, followed 
by 45 cycles for 15 seconds at 95°C, and 45 cycles
 
for 1 minute at 60°C. 
Statistical analysis 
Statistical analyses of data were performed using SPSS v.24.0 (IBM Corp., Armonk, NY, USA). 
Comparisons of the frequencies of the genotypes at the three loci were performed on 3x2 
contingency tables between cases and controls. Genotypic and allelic tests of association 
were performed using χ
2
 statistics or Fisher’s exact tests as appropriate. For all tests, nominal 
p-values are reported. The association between SNPs and the risk of HCC was estimated by 
calculating beta coefficients and their standard errors using logistic regression models 
adjusted for age, sex, BMI and diabetic status, assuming log-additive genetic effects. The 
interactions between polymorphic loci were examined by testing allelic and genotypic 
interaction terms in the logistic regression models. Results are expressed as odds ratios (OR) and 
95% confidence intervals (CI). 
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Population Attributable Fraction 
The population-attributable fraction (PAF) provides an epidemiological estimate of the 
proportion of the disorder that is attributable to the risk factor. Thus, it is an estimate of how 
much lower the frequency of HCC would be in the patients with alcohol-related cirrhosis, if 
the risk genotype(s) were eliminated from the population.  
The PAF was estimated for heterozygous and homozygous carriage using the formula: 
(x - 1)/x 
where x = (1- p)2 + 2p(1- p)OR1 + p2OR2; p is the allele frequency in alcohol-related cirrhosis, 
and OR1 and OR2 are the ORs associated with hetero- and homozygosity adjusted by sex, age, 
body mass index (BMI) and type 2 diabetes mellitus, respectively.[17]   
 
Combined PAF estimates were calculated based on the individual PAFs for each associated 
SNP, assuming no multiplicative interaction amongst the SNPs.[17]  
Ethics 
The study was approved by the ethics committees of the participating institutions; all 
included subjects provided written informed consent prior to inclusion into the study. 
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RESULTS 
The cases were significantly older than the controls; proportionately more were male, 
overweight and had comorbid type 2 diabetes mellitus (Table 1). However, the cases were 
significantly less likely to have decompensated liver disease (Table 1). 
Genotyping was completed for all three SNPs with call rates greater than 95%; there were 
significant differences in the genotyping call rates between cases and controls but the 
distributions of the missing data were random and not skewed. All markers followed Hardy-
Weinberg equilibrium (cutoff HWE P > 0.05) in both the cases and controls (Table 2). 
Allelic and genotypic associations of PNPLA3 rs738409 with HCC in alcohol-related cirrhosis 
were highly significant (Pallelic= 3.64×10
-20
, Pgeno= 6.14×10
-18
). The odds ratio (OR) for 
homozygous carriers of the risk allele PNPLA3 rs738409 G was 3.26 (95% CI: 2.50-4.25) 
compared to the risk in heterozygous carriers of 1.70 (95% CI: 1.37-2.10). The allelic and 
genotypic associations of TM6SF2 rs58542926 with HCC in alcohol-related cirrhosis were also 
highly significant at Pallelic= 8.93×10
-7
 and Pgenotypic= 7.74371×10
-6
, respectively. The OR for 
homozygous carriage of the risk allele TM6SF2 rs58542926 T was 3.32 (95% CI: 1.76-6.24), 
while the OR for heterozygous carriage was 1.46 (95% CI: 1.15-1.84). In contrast, neither 
heterozygous nor homozygous carriage of the MBOAT7 rs641738 T allele was associated with 
HCC risk; the allelic and genotypic levels of significance were Pallelic=0.639 and Pgenotypic=0.676 
respectively while corresponding ORs for homozygous and heterozygous carriage of the T 
allele were 1.07 (95% CI: 0.83-1.38) and 0.96 (95% CI: 0.77-1.20). 
The minor allele frequencies (MAF) of all three loci in the controls in the present study were 
in line with those observed in the previous GWAS in alcohol-related cirrhosis [12], but the 
frequencies of PNPLA3 rs738409 G and TM6SF2 rs58542926 T were higher in the cases.  The 
MAF for MBOAT7 rs641738 T was similar in cases and controls. 
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The robustness of the association of PNPLA3 rs738409 and TM6SF2 rs58542926 and the 
development of HCC was confirmed after adjustment for other known risk factors viz. age, 
sex, BMI and type 2 diabetes mellitus (Table 3). The lack of association with MBOAT7 
rs641738 did not change following adjustment for these confounders. 
The association of PNPLA3 rs738409 and TM6SF2 rs58542926 with HCC was consistent across 
the separate cohorts from Switzerland, Germany, Britain and Ireland, as was the lack of 
association with regard to MBOAT7 rs641738 (Supplementary Figures 1A-C).  
The PAF% for PNPLA3 rs738409 was 43.5% and for TM6SF2 rs58542926 11.4% yielding a 
combined PAF% of both risk loci of 49.9% (Table 4).  
The proportion of cases and controls who carried either no, one out of two, or both risk 
variants in PNPLA3 and TM6SF2 illustrated the aggregated risk due to co-carriage of risk loci 
(Figure 1). Thus, only 10% of the controls but approximately 20% of the cases carried both risk 
alleles. 
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DISCUSSION 
Elucidating the genetic background of chronic liver diseases is important as it will enable an 
individual’s risk to develop progressive liver damage to be assessed more precisely, and will 
allow greater insight into currently unknown molecular aspects of the underlying 
pathophysiology. Of particular importance is the definition of the risk factors predisposing an 
individual with an a priori cancer risk, i.e. cirrhosis, to the development of life-threatening 
malignancy particularly if defining the risk factors would allow development of a strategy for 
more individualized screening and targeted prevention.  
The present study provides data on the largest cohort of patients with HCC on a background 
of alcohol-related cirrhosis undertaken to date and provides further confirmation that the 
PNPLA3 rs738409 G allele is the strongest independent genetic risk factor for HCC in this 
patient population [10, 11]. The present analysis further expands the panel of genetic risk 
factors for HCC to include TM6SF2 rs58542926, albeit with lesser effect as reflected by its 
lower OR and PAF%. It also showed a lack of association with MBOAT7 rs641738. There is only 
limited information on the possible risks associated with carriage of TM6SF2 rs58542926 and 
MBOAT7 rs641738 and the development of HCC with which to compare the findings of the 
present study.   
Nischalke et al. in a relatively small, multicentre study found a significant risk association 
between carriage of rs2228603 in neurocan (NCAN) and the development of HCC in patients 
with alcohol-related cirrhosis [13]. This genetic variant had been linked the development of 
hepatic steatosis in a previous GWAS in nonalcoholic fatty liver disease (NAFLD) [18]. 
Subsequent genetic fine mapping showed that NCAN rs2228603 lies within 50 kb and is in 
strong linkage disequilibrium with TM6SF2 rs58542926 [19]. A subsequent exome-wide 
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analysis conclusively identified TM6SF2 rs58542926 as the more likely risk factor for 
progressive NAFLD in this genomic region [20]. Falleti et al. [14] analyzed a cohort of 511 
patients with cirrhosis of mixed aetiology, of whom 101 had HCC, and found an association 
between the risk of developing HCC and carriage of the TM6SF2 rs58542926 T allele in the 
226 patients with alcohol-related cirrhosis (Adjusted OR=2.57; p=0.035). They found no 
interaction between PNPLA3 rs738409 and TM6SF2 rs58542926 in relation to HCC risk. 
A recent candidate gene association study from Italy and the UK investigated the association 
between variants within MBOAT7 and HCC in a mixed cohort of patients with NAFLD, chronic 
hepatitis C and alcohol-related liver disease the majority of whom did not have cirrhosis [21]. 
The authors reported a significant association between MBOAT7 rs641738 and HCC in non-
cirrhotic patients with NAFLD, but only in the Italian cohort. The findings were not however 
replicated in a validation cohort of UK patients. The reasons for this discrepancy likely relates 
to the fact that development of HCC in people with non-cirrhotic alcohol- and viral-related 
liver disease in Western countries is very rare and hence the number of cases was small.  
Thus, the inability of these workers to replicate their findings may reflect the inconsistent of 
the chosen phenotypes studied and/or low statistical power.  
The lack of association between HCC risk and MBOATrs641738 is further supported by a 
recent candidate gene study in people with chronic hepatitis C which demonstrated that the 
influence of this variant is restricted to the transition from absence of fibrosis to mild fibrosis 
[22]. In this same study, no difference was observed in the MAF of MBOAT7rs641738 in a 
small subgroup of 75 people with HCV-related HCC within an entire cohort of 1,706 indicating 
a lack of statistical power. However, the present study was adequately powered to detect an 
allelic odds ratio of 1.18 with 80% power and hence the finding of no association between 
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MBOAT7 rs641738 and the development of HCC in alcohol–related cirrhosis is robust [23] and 
was consistent across all study subpopulation (Supplementary Figure 1C). 
In the present study carriage of risk alleles in PNPLA3 and TM6SF2 accounted for almost 50% 
of the population-attributable genetic risk for the development of HCC in patients with 
alcohol-related cirrhosis. The combined PAF% is usually lower than the sum of each individual 
PAR% but not in this instance. The odds ratio was, in fact, greater than 3 for homozygous 
carriage and ~1.5 for heterozygous carriage for both variants, and hence surprisingly high for 
a germline genetic risk factor in a complex disorder.  
The possibility that these genetic markers could be included in a stratification score to identify 
patients at high risk for HCC has to be considered. Hypothetically, screening intervals could be 
tailored according to the genetic signature in a given patient, applying longer intervals in 
those minimal inherited predisposition, and shorter periods for those who carry both risk 
alleles.  However, any such proposals would need to be tested in prospective surveillance 
studies designed to assess possible patient benefit. 
Anstee et al. [24] have recently looked at the clinical utility of PNPLA3 genotyping for 
stratifying the risk for developing HCC in patients with NAFLD in a reanalysis of the data 
published by Liu et al. [25].  They found that use of PNPLA3 genotyping alone to positively 
predict the risk of developing HCC was unlikely to be tenable. However, the negative 
predictive value (NPV) was substantially greater, suggesting that genotyping this SNP might 
have utility for selecting those individuals least likely to develop HCC and therefore least likely 
to benefit from surveillance. 
Using a similar approach the diagnostic test performance for PNPLA3 and TM6SF2 genotyping 
for the detection of HCC risk in the present study cohort showed a NPV of 72.5% for the 
combination PNPLA3 rs738409 GG and TM6SF2 rs58542926 *T. Based on these figures, a 
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schema for individual screening intervals is proposed with the caveat that any adoption must 
be subject to appropriate prospective evaluation (Table 5). 
The distinct genetic profiles of the alcohol-related cirrhosis risk genes with regards to liver 
carcinogenesis also have intriguing functional implications. The PNPLA3 rs738409 GG variant 
is considered a loss-of-function mutation and as such is less able to hydrolyze triglycerides 
from lipid droplets leading to lipid trapping in hepatocytes and increased lipotoxicity. Since 
progression of fibrosis is only weakly associated with the degree of steatosis [26], additional 
effects beyond mere lipid accumulation are suspected. Thus, PNPLA3 rs738409 has been 
functionally linked to increased levels of circulating pro-inflammatory mediator intracellular 
adhesion molecule 1 (ICAM-1) [27], which is also overexpressed in human HCC stem cells and 
circulating HCC tumor cells [28]. Furthermore, in patients with NAFLD PNPLA3rs738409 G 
allele was found to be associated with decreased levels of adiponectin which has important 
anti-inflammatory, anti-fibrotic and anti-carcinogenic properties [29]. Recent data in cell 
culture and mice xenografts also suggest an effect of PNPLA3 rs738409 on the activation of 
the interleukin (IL)-6-Janus kinase (JAK2)/Signal Transducers and Activators of Transcription 
(STAT3) pathway via fatty acid-mediated inflammation [30]. Therefore, functional studies 
linking the ’lipid droplet disease‘ caused by PNPLA3 malfunction to cancer may likely unravel 
interesting insights into the pathophysiology of HCC. 
While the promoting effect of PNPLA3 rs738409 on HCC evolution remains incompletely 
understood, even less is known about the possible role of genetic variation of TM6SF2 in this 
process. TM6SF2 is involved in the assembly and secretion of very low-density lipoproteins, 
similar to microsomal triglyceride transfer protein (MTTP), and thus a loss of function 
mutation would be compatible with lipid accumulation in hepatocytes. Accordingly, Sookoian 
et al. [31] performed allele-specific expression analyses of cDNA isolated from liver tissue 
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from patients with NASH and confirmed that expression levels of the rs58542926 T allele are 
reduced to about 56% of that of the wild type C allele. These findings suggest that carriage of 
the TM6SF2 T risk allele is associated with decreased hepatic gene and protein expression, 
leading to a loss of function similar to the mutant PNPLA3 variant. In turn, the wild type 
TM6SF2 protein has been associated with increased serum VLDL levels and an elevated 
cardiovascular risk [32], but less liver injury [33]. Whether and how there may be cross-talk 
between TM6SF2 and signaling pathways pertinent for HCC development beyond mere 
intracellular lipid accumulation and lipotoxicity remains to be elucidated. 
This study has its limitations, primarily the fact that it was undertaken retrospectively and was 
restricted to Caucasian people with alcohol-related cirrhosis. Thus the findings do not 
necessarily define the genetic risks for HCC development in people with liver disease of other 
aetiologies or to other ethnic groups. However, it also has its strengths, including the size of 
the study population, and the fact similar effect sizes were observed across the component 
geographical cohorts. Thus, the presented data provide robust evidence for a strong effect of 
PNPLA3 rs738409 on HCC risk in patients with alcohol-related cirrhosis. In addition, TM6SF2 
rs58542926 is identified and confirmed as a significant host genetic risk factor for HCC, while 
MBOAT7 rs641738 is not. In combination, PNPLA3 rs738409 and TM6SF2 rs58542926 account 
for almost 50% of the population-attributable risk for the development of HCC, and thus, 
should be evaluated further for stratification of patients at risk in screening programs. In 
addition, sight should not be lost of the fact that a significant proportion of the genetic 
variance still remains to be identified. 
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LEGENDS TO FIGURES 
 
Figure 1 
Proportion of cases with alcohol–related cirrhosis and HCC by carriage of the risk variants in 
PNPLA3 and TM6SF2. 
 
Supplementary figures 
Figure 1A 
Forrest plot displaying a consistent association of PNPLA3 rs738409 with HCC across different 
national cohorts. The association is similar in all three cohorts. 
 
Figure 1B 
Forrest plot displaying association of TM6SF2 rs58542926 with HCC in different national 
cohorts. The association is similar in all three cohorts. 
 
Figure 1C 
Forrest plots ahowing no significant association between MBOAT7 rs641738 with HCC in any 
of the three cohorts. 
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Table 1 
Characteristics of cases and controls included in the study 
 
Variable 
Total 
(n=1916) 
Cases  
(n= 751) 
Controls 
(n=1165) 
Significance 
(p) 
Proportion male 
(n: %) 
1496 (78) 679 (90) 817 (70) < 0.00001 
Age (yr) 58±11 61±10 55±10 < 0.00001 
BMI (kg/m
2
) 26.6±4.7 27.9±4.7 25.9±4.6 < 0.00001 
BMI (%) 
<25 
25-30 
>30 
36% 
42% 
21% 
26% 
42% 
32% 
43% 
42% 
15% 
 
 
< 0.00001 
Child Pugh Grade [16] (%) 
A 
B 
C 
 
35% 
40% 
26% 
 
48% 
36% 
16% 
 
27% 
42% 
31% 
 
 
< 0.00001 
Type II diabetes mellitus 
(n: %) 
27 (1.4) 42 (5.6) 18 (1.5) 
 
< 0.00001 
Data are reported as mean ± standard deviation or as number (%) 
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Table 2 
Genotypic and allelic frequencies of PNPLA3, TM6SF2 and MBOAT7 in people with alcohol-related cirrhosis with HCC (cases) and without (controls) 
MAF, minor allele frequency; OR, odds ratio 
 
SNP 
Total 
(n=1916) 
      
Unadjusted 
OR (CI 95%) 
Adjusted 
OR (CI 95%) 
P trend 
 
Pallelic 
 
Pgenotypic 
PNPLA3  CC CG GG MAF fCG (%) fGG (%) CG vs CC GG vs CC    
Cases  751 205 346 200 0.497 46% 27% 
1.70 [1.37-2.10] 3.26 [2.50-4.25] 5.45E-19 3.64E-20 6.14E-18 
Controls  1165 508 505 152 0.347 43% 13% 
TM6SF2  CC CT TT MAF (%) fCT (%) fTT (%) CT vs TT CC vs TT    
Cases  751 558 164 29 0.148 22% 4% 
1.46 [1.15-1.84] 3.32 [1.76-6.24] 1.22E-06 8.93E-07 7.74371E-06 
Controls  1165 957 193 15 0.096 17% 1% 
MBOAT7  CC CT TT MAF (%) fCT (%) fTT (%) CT vs TT CC vs TT    
Cases  751 203 363 185 0.488 48% 25% 
0.96 [0.77-1.20] 1.07 [0.83-1.38] 0.377 0.639 0.676 
Controls  1165 314 583 268 0.480 50% 23% 
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Table 3 
Multivariate analysis of factors associated with hepatocellular carcinoma in people with 
alcohol-related cirrhosis 
SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval 
* adjusted for age, gender, BMI, type II diabetes mellitus. 
SNP *Adjusted OR (95% CI) Significance (p) 
PNPLA3 rs738409:G 1.84 (1.55-2.18) 1.85×10
-12
 
PNPLA3 rs738409:CG 2.07 [1.58-2.73] 1.87×10
-07
 
PNPLA3 rs738409:GG 3.26 [2.31-4.60] 1.87×10
-11
 
TM6SF2 rs58542926:T 1.66 (1.30-2.13) 5.13×10
-05
 
TM6SF2 rs58542926:CT 1.67 [1.23-2.26] 1.03×10
-03
 
TM6SF2 rs58542926:TT 2.86 [1.34-6.12] 6.75×10
-03
 
MBOAT7 rs641738:T 1.04 (0.88-1.24) 0.61 
MBOAT7 rs641738:CT 0.90 [0.67-1.20] .473 
MBOAT7 rs641738:TT 1.09 [0.78-1.53] .619 
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Table 4 
Population-attributable fraction of each variant with regard to the genetic risk of HCC in 
alcohol-related cirrhosis alone, and in combination. 
 
 
Genetic variant 
*Population Attributable Fraction  
(%) 
PNPLA3 rs738409 43.5 
TM6SF2 rs58542926 11.5 
PNPLA3 + TM6SF2 (combined) 49.9 
 
* Estimated for heterozygous and homozygous carriage in one equation. 
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Table 5 
Proposed screening intervals for HCC of people with alcohol-related cirrhosis based on the 
genetic signature 
 
 
Genetic background Screening interval 
PNPLA3 rs738409 WT (CC), TM6SF2 rs58542926:CC 24 months 
TM6SF2 rs58542926:T* and PNPLA3 rs738409 CC 12 months 
TM6SF2 rs58542926:CC and PNPLA3 rs738409 GG 6 months 
PNPLA3 rs738409 GG and TM6SF2 rs58542926:T* 3 months 
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